文献速递产科

宫内真空诱导止血装置用于产后出血的快速治疗

Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage.
PubMed 文献 · Obstet Gynecol · 2020-01-01

在美国12个中心开展的多中心、前瞻性、单臂治疗研究,评估宫内真空诱导止血装置治疗产后出血的有效性和安全性。106例接受治疗者中94%(100/106,95%CI 88-98%)无需升级干预即控制异常出血,中位控制时间3分钟(四分位距2.0-5.0),8例不良事件均经治疗缓解。

要点

  • 106例接受装置连接真空治疗者中94%(100/106,95%CI 88-98%)无需升级干预即成功控制出血。
  • 100例成功控制者中,连接真空后中位3分钟(四分位距2.0-5.0)达到异常出血的确定性控制。
  • 35例需输注1-3单位红细胞,5例需输注4单位及以上红细胞。

核心结论

  • 宫内真空诱导止血可能为异常产后子宫出血或产后出血提供一种新的快速有效治疗选择,并有可能预防严重孕产妇并发症和死亡。

研究设计与样本

  • 多中心、前瞻性、单臂治疗研究,在美国12个中心开展,评估一种利用低水平真空诱导子宫肌层收缩以控制异常产后子宫出血和产后出血的新型宫内装置。
  • 共入组107例原发性产后出血或异常产后子宫出血参与者,其中106例接受装置连接真空的研究治疗。
  • 主要有效性终点为使用该装置控制异常出血且无需升级干预的参与者比例;主要安全性终点为装置相关不良事件的发生率、严重程度和严重性。

主要发现

  • 106例接受装置连接真空治疗者中,94%(100/106,95%CI 88-98%)成功治疗。
  • 100例成功治疗者中,连接真空后达到异常出血确定性控制的中位时间为3分钟(四分位距2.0-5.0)。
  • 报告8例被认为可能与装置或操作相关的不良事件,均为研究已列出的风险,且均经治疗缓解、无严重临床后遗症。
  • 35例需输注1-3单位红细胞,5例需输注4单位及以上红细胞。
  • 多数研究者报告该装置易于使用(98%)并会推荐使用(97%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of an intrauterine vacuum-induced hemorrhage-control device for postpartum hemorrhage treatment. METHODS: A multicenter, prospective, single-arm treatment study of a novel intrauterine device that uses low-level vacuum to induce uterine myometrial contraction to achieve control of abnormal postpartum uterine bleeding and postpartum hemorrhage was undertaken at 12 centers in the United States. The primary effectiveness endpoint was the proportion of participants in whom use of the intrauterine vacuum-induced hemorrhage-control device controlled abnormal bleeding without requiring escalating interventions. The primary safety endpoint was the incidence, severity, and seriousness of device-related adverse events. Secondary outcomes included time to bleeding control, rate of transfusion, and device usability scored by each investigator using the device. RESULTS: Of 107 participants enrolled with primary postpartum hemorrhage or abnormal postpartum uterine bleeding, 106 received any study treatment with the device connected to vacuum, and successful treatment was observed in 94% (100/106, 95% CI 88-98%) of these participants. In those 100 participants, definitive control of abnormal bleeding was reported in a median of 3 minutes (interquartile range 2.0-5.0) after connection to vacuum. Eight adverse events deemed possibly related to the device or procedure were reported, all of which were outlined as risks in the study and all of which resolved with treatment without serious clinical sequelae. Transfusion of 1-3 units of red blood cells was required in 35 participants, and five participants required 4 or more units of red blood cells. The majority of investigators reported the intrauterine vacuum-induced hemorrhage-control device as easy to use (98%) and would recommend it (97%). CONCLUSION: Intrauterine vacuum-induced hemorrhage control may provide a new rapid and effective treatment option for abnormal postpartum uterine bleeding or postpartum hemorrhage, with the potential to prevent severe maternal morbidity and mortality. FUNDING SOURCE: Alydia Health, Inc. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02883673.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. D'Alton ME, Rood KM, Smid MC, et al. Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage. Obstet Gynecol. 2020. PMID: 32909970. doi:10.1097/AOG.0000000000004138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。